Xavier Doumen
Europe Guide 2024
Band 6 : Corporate/M&A: High-end Capability
Band 6
Articles, highlights and press releases
2 items provided by Hogan Lovells (Paris) LLP
Hogan Lovells advises Shire in ex-U.S. closing of its US$2.4bn business sale to Servier S.A.S.
Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
Hogan Lovells advises Shire in ex-U.S. closing of its US$2.4bn business sale to Servier S.A.S.
Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
Hogan Lovells advises Shire in ex-U.S. closing of its US$2.4bn business sale to Servier S.A.S.
Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.
Hogan Lovells advises Shire in ex-U.S. closing of its US$2.4bn business sale to Servier S.A.S.
Hogan Lovells represented global biotechnology company Shire plc. in the ex-U.S. closing of the sale of its oncology business to Servier S.A.S., an independent international pharmaceutical company, for US$2.4 billion in cash.